All In Biotech

Drug Trial Radar · NCT00943826

A Study of Bevacizumab (Avastin®) in Combination With Temozolomide and Radiotherapy in Participants With Newly Diagnosed Glioblastoma

A Randomized, Double-Blind, Placebo-Controlled, Multicenter Phase III Trial of Bevacizumab, Temozolomide and Radiotherapy, Followed by Bevacizumab and Temozolomide Versus Placebo, Temozolomide and Radiotherapy Followed by Placebo and Temozolomide in Patients With Newly Diagnosed Glioblastoma

Last checked: Nov 20, 2026Latest source record: Sep 25, 2017 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 921 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

921

Actual

Start

Jun 29, 2009

Primary completion

Feb 28, 2013

Study completion Sep 9, 2015

Sponsor

Lead sponsor
Hoffmann-La RocheRoche (Genentech) (RHHBY)
Sponsor type
Industry
First posted
Jul 22, 2009

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This 2 arm study investigated the efficacy and safety of the addition of bevacizumab to the current standard of care (multimodality therapy of concurrent radiotherapy plus temozolomide followed by adjuvant temozolomide) as compared to the current standard of care alone. Participants were randomly assigned to either the bevacizumab (10 milligrams per kilogram (mg/kg) intravenously \[IV\] once every 2 week \[q2w\]) or the placebo arm, in combination with radiation therapy (total dose 60 Gray \[Gy\], administered as 2 Gy fractions, 5 days/week) plus temozolomide (75 milligrams per meter squared \[mg/m\^2\] oral administration \[po\] daily) for 6 weeks. After a 4 week treatment break, participants continued to receive bevacizumab (10 mg/kg IV q2w) or placebo, plus temozolomide (150-200 mg/m\^2 po daily on days 1-5 of each 4 week cycle) for 6 cycles of maintenance treatment or until disease progression or unacceptable toxicity, whichever occured first. Following the maintenance phase, bevacizumab (15 mg/kg iv every 3 weeks \[q3w\]) or placebo monotherapy continued. The time on study treatment was until disease progression.

Conditions

  • Glioblastoma

Interventions

  • BevacizumabDrug

    10 mg/kg intravenously q2w in the Concurrent and Maintenance Phases. 15 mg/kg intravenously q3w in the Monotherapy Phase.

  • TemozolomideDrug

    75 mg/m\^2 once daily for 6 weeks, followed by 150-200 mg/m\^2 once daily on days 1-5 of six 4 week cycles.

  • Radiation therapyRadiation

    30 fractions of 2 Gy delivered on days 1-5 per week for 6 weeks.

  • PlaceboDrug

    Intravenously q2w in the Concurrent and Maintenance Phases and q3w in the Monotherapy Phase.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Co-Primary: Progression-free Survival (PFS) as Assessed by InvestigatorTime frame: Randomization until PFS Event [Until data cutoff= 31 March 2012 (up to 31.4 months)
  2. Co-Primary: Overall Survival (OS)Time frame: Randomization until OS Event (Until data cutoff= 28 February 2013 [up to 42.2 months])

Locations

133 sites in 24 countries. Site status is shown where the registry gives one.

  • University of Alabama At Birmingham; Neuro-Oncology

    Birmingham, Alabama

  • UCLA

    Los Angeles, California

  • University of Colorado

    Aurora, Colorado

  • Moffitt Cancer Center

    Tampa, Florida

  • Oncology-Evanston Nthwest Healthcare Kellogg Cancer Care Ctr

    Evanston, Illinois

  • Henry Ford Health System

    Detroit, Michigan

  • Hatton Research Institutes

    Cincinnati, Ohio

  • Sarah Cannon Cancer Center and Research Institute

    Nashville, Tennessee

  • University of Virgina

    Charlottesville, Virginia

  • Prince of Wales Hospital; Department of Medical Oncology

    Randwick, New South Wales, Australia

  • North Shore Private Hospital; Northern Specialist Centre

    St Leonards, New South Wales, Australia

  • Royal North Shore Hospital; Department of Medical Oncology

    St Leonards, New South Wales, Australia

  • Princess AleXandra Hospital; Department of Medical Oncology

    Woolloongabba, Queensland, Australia

  • Calvary North Adelaide; North Adeliade Oncology Centre

    North Adelaide, South Australia, Australia

  • Royal Melbourne Hospital; Hematology and Medical Oncology

    Parkville, Victoria, Australia

  • Sir Charles Gairdner Hospital

    Nedlands, Western Australia, Australia

  • Clin Univ de Bxl Hôpital Erasme

    Brussels, Belgium

  • Cliniques Universitaires St-Luc

    Brussels, Belgium

  • UZ Antwerpen

    Edegem, Belgium

  • AZ Sint Lucas (Sint Lucas)

    Ghent, Belgium

  • CHU Sart-Tilman

    Liège, Belgium

  • AZ Delta (Campus Wilgenstraat)

    Roeselare, Belgium

  • Tom Baker Cancer Centre-Calgary

    Calgary, Alberta, Canada

  • Cross Cancer Institute ; Dept of Medical Oncology

    Edmonton, Alberta, Canada

  • BC Cancer Agency, Vancouver Clinic; Dept. of Medical Oncology

    Vancouver, British Columbia, Canada

  • CancerCare Manitoba; Neuro-Oncology

    Winnipeg, Manitoba, Canada

  • Hamilton Health Sciences - Juravinski Cancer Centre

    Hamilton, Ontario, Canada

  • Cancer Centre of Southeastern Ontario; Kingston General Hospital

    Kingston, Ontario, Canada

  • London Health Sciences Centre

    London, Ontario, Canada

  • Ottawa Hospital Regional Cancer Centre; Neuro-Oncology

    Ottawa, Ontario, Canada

  • Sunnybrook Odette Cancer Centre

    Toronto, Ontario, Canada

  • Princess Margaret Hospital; Pencer Brain Tumour Centre, 18-727

    Toronto, Ontario, Canada

  • Hopital Notre-Dame

    Montreal, Quebec, Canada

  • McGill University; Montreal Neurological Institute; Oncology

    Montreal, Quebec, Canada

  • Chuq - Hopital Hotel Dieu de Quebec

    Québec, Quebec, Canada

  • Saskatoon Cancer Centre; Uni of Saskatoon Campus

    Saskatoon, Saskatchewan, Canada

  • Aalborg Universitetshospital, Klinik Kirurgi-Kræft, Onkologisk afd.

    Aalborg, Denmark

  • Righospitalet, Hæmatologisk Klinik

    København Ø, Denmark

  • Odense Universitetshospital, Onkologisk Afdeling R

    Odense, Denmark

  • Hopital Avicenne; Rhumatologie

    Bobigny, France

Showing 40 of 133 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.